Form 10-Q Table of Contents Preclinical and clinical data have demonstrated the potential for anti-myostatin therapies to produce physical and metabolic changes that are highly relevant to individuals living with overweight and obesity, including reducing total body fat and visceral adiposity, and improving insulin sensitivity and bone mineral density, while increasing lean muscle mass. In the fourth quarter of 2021, we initiated a Phase 1a/1b trial in multiple myeloma patients using its antibody recruiting ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________________________________________________ FORM 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to __ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Biohaven Ltd. WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41477 (Exact Name of Registrant as Specified in its Charter) British Virgin Islands Not applicable (State or other jurisdiction of incorporation ...

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Q4 2021 Earnings Conference Call February 25, 2022 8:30 AM ET Company Participants Caroline Dircks – Vice President, Corporate Operations Vlad Coric – Chief Executive Officer Matthew Buten – Chief Financial Officer BJ Jones – Chief Commercial Officer Elyse Stock – Chief Medical Officer Michael Bozik – President, Biohaven Labs Steven Dworetzky – Senior Vice President, Biohaven Labs Cliff Bechtold – President and General Manager, Biohaven Ireland Confer ...

NEUROINNOVATION® We Demand More for Patients. 4th Quarter and Full Year 2021 Earnings February 25, 2022 Ellie, living with migraine NYSE:BHVN © 2022 Biohaven Pharmaceuticals. All rights reserved. Agenda | --- | |---------------------------------------------------------------------------------------------------------------| | | | Opening Remarks \| Caroline Dircks, Ph.D., Vice President Corporate Operations | | Company Achievements \| Vlad Coric, M.D., Chief Executive Officer | | 4Q and Year End 2021 Financi ...

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Q3 2021 Earnings Conference Call November 9, 2021 8:00 AM ET Company Participants Caroline Dircks – Vice President Corporate Operations Vlad Coric – Chief Executive Officer Jim Engelhart – Chief Financial Officer Bj Jones – Chief Commercial Officer Elyse Stock – Chief Medical Officer Nick Lagunowich – Global President Conference Call Participants Ken Cacciatore – Cowen Alley Bratzel – Piper Sandler Paul Choi – Goldman Sachs Jeff Hung – Morgan Stanley ...

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Q2 2021 Earnings Conference Call August 9, 2021 8:30 AM ET | --- | |--------------------------------------------| | | | Company Participants | | Caroline Dircks - VP, Corporate Operations | | Vlad Coric - CEO | | Jim Engelhart - CFO | | BJ Jones - CCO | | Elyse Stock - CMO | | Conference Call Participants | | Paul Choi - Goldman Sachs | | Ken Cacciatore - Cowen | | Chris Raymond - Piper Sandler | | Charles Duncan - Cantor Fitzgerald | | Laura Chico - ...

Ellie, living with migraine Ellie, living with migraine 2nd Quarter 2021 Earnings August 9, 2021 e NYSE:BHVN © 2021 Biohaven Pharmaceuticals. All rights reserved. Agenda Opening Remarks | Caroline Dircks, Ph.D. Vice President Corporate Operations Second Quarter Summary and Recent Events| Vlad Coric, M.D. Chief Executive Officer 2Q2021 Financial Results | Jim Engelhart, C.P.A. Chief Financial Officer Commercial Events | BJ Jones, M.B.A. Chief Commercial Officer Migraine and Common Disease R&D Update | Elyse ...

Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Q1 2021 Results Conference Call May 10, 2021 8:30 AM ET Company Participants Clifford Bechtold - Chief Operating Officer Vladimir Coric - Chief Executive Officer Jim Engelhart - Chief Financial Officer BJ Jones - Chief Commercial Officer Dr. Elyse Stock - Chief Medical Officer Conference Call Participants Kenneth Cacciatore - Cowen and Company Kyuwon Choi - Goldman Sachs Group Christopher Joseph - Raymond Piper Sandler Laura Kathryn - Wedbush Securitie ...